Research programme: respiratory syncytial virus vaccine - DBV Technologies/INRA

Drug Profile

Research programme: respiratory syncytial virus vaccine - DBV Technologies/INRA

Alternative Names: RSV-NanoViaSkin; Viaskin-N; Viaskin-N-FsII

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator DBV Technologies; INRA
  • Class Immunotherapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 03 Mar 2017 Immunogenicity data from a preclinical trial in Respiratory syncytial virus infections presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAI-2017)
  • 16 Jul 2016 No recent reports of development identified for research development in Respiratory-syncytial-virus-infections(In infants, In neonates, Prevention) in France (Intradermal, Patch)
  • 15 Jan 2013 DBV Technologies and INRA receive grant from the French National Research Agency for Respiratory syncytial virus vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top